Exact Sciences Corp. announced its participation in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present ten abstracts highlighting innovations in cancer detection and precision oncology. The event is scheduled from May 30 to June 3, 2025, in Chicago.
The presentations will include new data on several key products: the Oncodetect molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score test, and the Cologuard test. These developments are part of Exact Sciences’ ongoing efforts to enhance cancer care through scientific advancements.
Dr. Rick Baehner, MD, chief medical officer for Precision Oncology at Exact Sciences, stated: “The data Exact Sciences will present at ASCO 2025 reflect the scientific rigor and clinical significance of our expanding portfolio and pipeline. From MRD to MCED to CRC screening, we are advancing evidence-based innovations that help empower providers and deliver crucial answers to patients.”
Evidence supporting the Cologuard test continues to grow with research into repeat screening. The Oncotype DX test remains a standard tool for predicting chemotherapy benefits for breast cancer patients.
Data from the Beta-CORRECT study reinforces the clinical foundation of the Oncodetect test for colorectal cancer treatment decisions. A multi-year study is also evaluating MRD testing’s impact on community care settings.
In addition, a modeling study suggests that annual MCED testing could significantly reduce late-stage cancer incidence and mortality among high-risk groups. This research supports Exact Sciences’ upcoming launch of Cancerguard EX, an MCED lab-developed test set for release later this year.
